Clinical Trials
38 trialsVOTRAGE
Institut Claudius Regaud
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
University of Washington
Pazopanib Maintenance Phase II
Ludwig-Maximilians - University of Munich
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
EVA
Heidelberg University
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
NIVOSWITCH
AIO-Studien-gGmbH
PAZOFOS
The Christie NHS Foundation Trust
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Emerald Clinical Inc.
NOPASS
Heidelberg University
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Washington University School of Medicine
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
PASART-2
The Netherlands Cancer Institute
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
Hellenic Cooperative Oncology Group
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
University of Arizona
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Memorial Sloan Kettering Cancer Center
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Pazopanib for Metastatic Alveolar Soft Part Sarcoma
Seoul National University Hospital
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
National Cancer Institute (NCI)
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Memorial Sloan Kettering Cancer Center
OPERA
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
University of Chicago
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Stanford University
DFSP-PAZO
Assistance Publique - Hôpitaux de Paris
Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer
Hellenic Oncology Research Group
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
New Mexico Cancer Research Alliance
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
Washington University School of Medicine
Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
GlaxoSmithKline
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
GlaxoSmithKline
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Illinois CancerCare, P.C.
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
Illinois CancerCare, P.C.
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Northwestern University